ZimVie (NASDAQ:ZIMV – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.550-0.700 for the period, compared to the consensus estimate of 0.590. The company issued revenue guidance of $450.0 million-$460.0 million, compared to the consensus revenue estimate of $453.9 million.
Wall Street Analyst Weigh In
Separately, Needham & Company LLC increased their price target on ZimVie from $20.00 to $23.00 and gave the stock a buy rating in a report on Friday.
Get Our Latest Report on ZimVie
ZimVie Stock Down 15.2 %
ZimVie (NASDAQ:ZIMV – Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported $0.13 EPS for the quarter. The company had revenue of $116.81 million during the quarter. ZimVie had a negative net margin of 63.84% and a positive return on equity of 2.09%. During the same period in the previous year, the firm earned $0.17 earnings per share. On average, equities research analysts expect that ZimVie will post 0.63 EPS for the current fiscal year.
About ZimVie
ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.
Recommended Stories
- Five stocks we like better than ZimVie
- What is Forex and How Does it Work?
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Retail Stocks Investing, Explained
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- How to Effectively Use the MarketBeat Ratings Screener
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.